-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Why Is FibroGen (FGEN) Stock Down 44% Today?
FibroGen stock is down on Wednesday as FGEN investors react to the company's failed clinical trials for its pancreatic cancer treatment.
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
Investors should consider the long term prospects of the following three healthcare stocks as the U.S. population ages.
3 Biotech Stocks That Could Make Your Summer Unforgettable
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns.
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
Cassava Sciences has announced plans to extend trials for its Alzheimer’s treatment drug. This news isn't helping SAVA stock.
Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?
CNS Pharmaceuticals stock is falling hard on Tuesday as CNSP investors aren't happy about its latest license expansion.
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
Processa Pharmaceuticals stock is up on Tuesday as PCSA investors react to approval for a Phase 2 clinical trial of NGC-Cap.
Why Is Imunon (IMNN) Stock Up 259% Today?
Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial.
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year.
Unlocking the Next 3 Trillion-Dollar Stock Opportunities
Investors might want to consider the potential of these three superstars poised to become future trillion dollar stocks.
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning.
The 3 Best Biometric Security Stocks to Buy Now
Investors interested in small scale and specialized sectors might want to consider looking into these best biometric security stocks.
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
The investing guru likes to take the pulse of where the world will be tomorrow and these Cathie Wood stocks reflect that vision.
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price.
3 Breakthrough Stocks Under $10 Set for Massive Upside
Discover the top breakthrough stocks under $10 with strong fundamentals and strategic advantages to hit massive upside.
Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.
ABT stock is in focus on ruling news. Abbott faced a suit last year over the closing of its Michigan plant resulting in a formula shortage.
Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates
The good news on Lomecel-B comes at an opportune time for Longeveron and LGVN stock -- it could attract a buyer.
